Zydol SR 50mg
- Name:
Zydol SR 50mg
- Company:
Grunenthal Pharma Ltd.
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 09/03/20

XPIL
Package leaflet: Information for the user
Package leaflet: Information for the user
1. What ZYDOL SR is and what it is used for
1. What ZYDOL SR is and what it is used for
2. What you need to know before you take ZYDOL SR
2. What you need to know before you take ZYDOL SR
3. How to take ZYDOL SR
3. How to take ZYDOL SR
4. Possible side effects
4. Possible side effects
5. How to store ZYDOL SR
5. How to store ZYDOL SR
6. Contents of the pack and other information
6. Contents of the pack and other information
Click on this link to Download PDF directly
Grunenthal Pharma Ltd.

Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 9 March 2020 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Free text change information supplied by the pharmaceutical company
Information added on sleep related breathing disorders
Updated on 9 March 2020 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Information added on sleep-related breathing disorders
Updated on 25 February 2019 PIL
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 6 - date of revision
Updated on 25 February 2019 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 18 June 2018
Updated on 29 May 2018 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Update to marketing authorisation holder and PA number
Updated on 25 May 2018 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.4
- Updated text on dependence and treatment discontinuation
- Text added on CYP2D6 metabolism
- Text added on available information on the use in post-operative children
- Text added on the use in children with compromised respiratory function
Section 4.6
- Update to breast-feeding section
Section 4.8
- Update on how to report adverse events to the MHRA
Section 5.2
- Deleted ’Up to now, clinically relevant interactions have not been reported'
Section 7 : MA holder changed to Grunenthal Pharma Ltd
Section 8: MA number changed to PA 2242/5/6
Section 10: Date of revision as 01 May 2018
Updated on 18 May 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - use in children and adolescents
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 6 - marketing authorisation holder
- Change to section 6 - marketing authorisation number
- Change to section 6 - date of revision
Updated on 10 May 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - use in children and adolescents
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 19 October 2016 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 19 October 2016 SPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.2 Posology and method of administration:
Reference to section 5.1 included
Section 5.1 Pharmacodynamic properties:
Information about paediatric population added
Section 5.2 Pharmacokinetic properties:
Information about paediatric population added
Updated on 21 July 2015 SPC
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Details of adverse event reporting changed from IMB to HPRA.
Updated on 21 July 2015 PIL
Reasons for updating
- New PIL for new product
Updated on 21 July 2015 PIL
Reasons for updating
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 4 February 2014 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 2 - formatting changes
Section 4.8 - addition of hypoglycaemia is a side effect with unknown frequency
- reporting of side effect
Section 10 - September 2013
Updated on 4 February 2014 PIL
Reasons for updating
- Change to side-effects
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 12 September 2013 SPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.9 - Overdose
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.1 - List of excipients
- Change to section 6.3 - Shelf life
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
- Editorial changes to sections 1,2, 4.2, 4.3, 4.4, 4.7, 4.9, 5.2, 5.3, 6.1, 6.3, 6.6, 10.
- Section 4.5
o Added information on Serotonin-norepinehphrine reuptake inhibitors (SNRIs) induced convulsions can be increased by tramadol.
o Added Symptoms/signs of serotonin syndrome
- Section 4.6
o Statement on fertility included
- Section 4.8
o Included adverse reaction relating to : Immune system disorders, investigations, vascular disorders, metabolism disorders
o Updates to adverse reactions relating to: cardiac disorders, nervous system disorders, psychiatric disorders, Eye disorders, respiratory, thoracic and mediastinal disorders, gastro intestinal disorders, skin disorders, hepatobiliary disorders, renal disorders and general disorders
Updated on 6 September 2013 PIL
Reasons for updating
- Change of contraindications
- Change to side-effects
- Change to date of revision
- Improved electronic presentation
Updated on 19 July 2011 SPC
Reasons for updating
- Change to section 3 - Pharmaceutical form
- Change to section 4.8 - Undesirable effects
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.8, ',' have been removed in the frequencies and replaced with 'to' (format change).
Section 9, the 'Date of last renewal' has been added.
Section 10, the 'Date of revision of the text' has been updated as per the issued PA Schedule.
Updated on 15 July 2011 PIL
Reasons for updating
- Change to improve clarity and readability
Updated on 15 July 2011 PIL
Reasons for updating
- Improved electronic presentation
Updated on 10 June 2010 PIL
Reasons for updating
- Change to storage instructions
- Change to side-effects
- Change to drug interactions
- Change to information about pregnancy or lactation
- Change to information about driving or using machinery
- Change to further information section
- Change to appearance of the medicine
- Change to dosage and administration
Updated on 9 June 2010 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.1 - List of excipients
- Change to section 6.3 - Shelf life
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
SPC section 4.9 Overdose, has been updated to include information about gastrointestinal decontamination with activated charcoal.
Updated on 6 November 2009 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 31 October 2007 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)